Clinical Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yoshizaki, T.
Right arrow Articles by Furukawa, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yoshizaki, T.
Right arrow Articles by Furukawa, M.
Clinical Cancer Research Vol. 7, 1946-1951, July 2001
© 2001 American Association for Cancer Research

Regular Articles

Induction of Interleukin-8 by Epstein-Barr Virus Latent Membrane Protein-1 and Its Correlation to Angiogenesis in Nasopharyngeal Carcinoma

Tomokazu Yoshizaki1, Toshiyuki Horikawa, Ren Qing-chun, Naohiro Wakisaka, Hajime Takeshita, Tzung-Shiahn Sheen, Shiann-Yann Lee, Hiroshi Sato and Mitsuru Furukawa

Department of Otolaryngology, School of Medicine [T. Y., T. H., R. Q-C., N. W., H. T., M. F.] and Department of Molecular Oncology and Virology, Cancer Research Institute [R. Q-C., H. S.], Kanazawa University, Kanazawa 920-8641, Japan, and Department of Otolaryngology, School of Medicine, National Taiwan University, Taipei 10016, Taiwan, Republic of China [T-S. S., S-Y. L.]


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Purpose: The EBV latent membrane protein-1 (LMP-1) is a multifunctional protein. Recently, the contribution of LMP-1 to the metastasis of nasopharyngeal carcinoma (NPC) has been suggested. Angiogenesis is a key step for metastasis. Thus, the association of LMP-1 to neovascularization of NPC was examined in this study.

Experimental Design: The association of LMP-1 to angiogenesis in 39 patients with NPC was evaluated by immunohistochemical study, and then induction of angiogenic factors by LMP-1 was examined by ELISA and luciferase reporter assay.

Results: In an immunohistochemical study, the expression of LMP-1 was significantly correlated to microvessel counts (P = 0.0003), suggesting that LMP-1 may induce some angiogenic factors. Therefore, we studied the relationship between LMP-1 expression and interleukin-8 (IL-8), vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) expression by immunohistochemical analysis. IL-8, VEGF, and bFGF expression were correlated to microvessel counts, but only IL-8 expression was significantly correlated to LMP-1 expression (P < 0.0001). Transfection with LMP-1 expression plasmid induced IL-8 protein expression in C33A cells. The expression of LMP-1 transactivated IL-8 promoter, as demonstrated by IL-8 promoter luciferase reporter assay. Mutation of the nuclear factor {kappa}B responsive element in the IL-8 promoter region completely abolished transactivation by LMP-1, whereas mutation of the activator protein responsive element did not affect promoter activity.

Conclusion: These results suggested that LMP-1 induces expression of IL-8 through the nuclear factor {kappa}B binding site, which may contribute in part to angiogenesis in NPC.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Angiogenesis is a key step in tumor growth, invasion and metastasis. Massive formation of blood vessels at the tumor site increases the opportunity for tumor cells to enter the circulation. Thus, microvessel density is considered to influence tumor metastasis and consequently prognosis in various human cancers (1) . VEGF,2 bFGF and IL-8 are prominent angiogenic molecules. These molecules have been demonstrated to influence microvessel synthesis in various tumors (2 , 3) .

EBV is a ubiquitous human {gamma} herpes virus and is associated to several human malignant neoplasms such as endemic Burkitt lymphoma and NPC (4 , 5) . LMP-1 is the principal EBV oncoprotein. LMP-1 is essential for immortalization of B lymphocytes and transforms rodent fibroblasts and human keratinocytes (6 , 7) . In addition to such transforming properties, LMP-1 is associated to down-regulation of E-cadherin, induction of MMP9, and up-regulation of cell motility (8, 9, 10) . Thus, LMP-1 has been suggested to contribute to invasion and metastasis. As angiogenesis is associated to tissue remodeling, which resembles tumor invasion, it is of interest to determine whether multifunctional LMP-1 protein could contribute to microvessel synthesis (11) .

In this study, we examined the role of LMP-1 in angiogenesis of NPC.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Tissue Samples.
Thirty-eight specimens were obtained from patients with NPC who underwent biopsy at the National Taiwan University Hospital from 1996 to 1997. They were composed of three squamous cell carcinomas (WHO type I), 15 nonkeratinizing carcinomas (WHO type II), and 20 undifferentiated carcinomas (WHO type III). Twenty-nine patients were male, and nine patients were female (mean age, 54.9 years; range, 22–81years). Biopsy specimens were embedded in OCT compound (Miles, Elkhart, IN), frozen immediately, and stored at -80C.

Immunohistochemical Analysis.
Immunohistochemical studies were performed using the avidin-biotin-complex method as described previously (12 , 13) . Frozen sections 5 µm thick were fixed with 100% ethanol. Endogenous peroxidase was blocked with Endo-blocker (Biomeda, Foster City, CA) and nonspecific reaction was blocked with normal sheep serum (DAKO, Copenhagen, Denmark), then incubated with primary antibodies at 4°C overnight. Primary antibodies against LMP-1 (CS1-4; DAKO), IL-8 (RS0002–08; R&D Systems, Inc., Minneapolis, MN), VEGF (A-20; Santa Cruz Biotechnology, Santa Cruz, CA), bFGF (SC-79G; Santa Cruz Biotechnology), and vWF (A0082; DAKO JAPAN, Kyoto, Japan) were used. The samples were incubated with a universal secondary antibody (Research Genetics, Huntsville, AL) containing biotinylated goat antimouse immunoglobulin and horseradish peroxidase-conjugated streptoavidin and then 3, 3'-diaminobenzidine tetrahydrochloride as a chromogen and hematoxylin as a nuclear counterstain. NPC sections that had been used in previous studies were used as positive controls for LMP-1, VEGF, and vWF staining (12 , 14) . Human placenta sections were used as positive controls for bFGF, and tonsil sections were used as positive controls for IL-8. The specificity of the staining was confirmed using nonimmune serum instead of the primary antibodies as a negative control.

Microvessel Counting.
Blood vessels were identified by anti-vWF antibody staining. The area of tumor that showed the most dense neovascularization was found by light microscopy at x10. Then, microvessels were counted at x400. These assessments were performed by two observers (T. Y. and T. H.). The highest number of microvessels identified within any single x400 field was defined as the microvessel index of the tumor.

Evaluation of Immunohistochemical Staining for LMP-1, VEGF, bFGF, and IL-8.
The stained specimens were examined independently by two of the authors (T. Y. and T. H.). In each case, two arbitrary separate microscopic fields (x200) containing >200 tumor cells were evaluated. These two arbitrary areas were selected from the area where microvessels were counted. After counting both immunoreactive cells and the total number of tumor cells, the average percentages of immunoreactive cells were calculated, without knowledge of the clinical data, and the results were reviewed by the other author. The average percentage of immunostained cells was defined as the expression score and was used for statistic analyses.

Statistical Analysis.
The data were analyzed with a Macintosh personal computer (Apple Computer, Cupertino, CA) with Stat View software (Abacus Concepts, Berkeley, CA). Statistical analysis was performed by Spearman’s correlation coefficient by rank test and Pearson’s correlation coefficient analysis, with Ps of <0.05 considered to indicate statistical significance.

Plasmid, Cell Line, and Transient Transfection.
The LMP-1 expression plasmid LMP1 was constructed as described previously (10) . Using the primers 5'-TTAGATCTGTGATGACTCAGGTTTGCCCTG-3' and 5'-GTCCTAGAAGCTTGTGTGCTCTGCTG-3', the 169-bp IL-8 promoter fragment (-130 to +39 relative to the transcriptional initiation site) was amplified by PCR from human genomic DNA and inserted into the multiple cloning site of the pGL3-Basic Vector (Promega, Madison, WI) to generate a construct containing the firefly luciferase gene as a reporter (pIL-8-Luc; Ref. 15 ). Mutations in NF{kappa}B- and AP-1-binding DNA sequences were generated by PCR using a site-directed mutagenesis kit (Takara, Otsu, Japan). The NF{kappa}B binding sequence in the IL-8 promoter TGGAATTTCC was mutated to TTAACTTTCC ({kappa}B-mut) and the AP-1 binding sequence TGAGTCA was mutated to TGATATC (AP-1-mut). The C33A cell line, derived from human cervical squamous cell carcinoma, was used according to our previous experiment. C33A cells (1 x 105) were cultured with DMEM supplemented with 5% fetal bovine serum for 24 h, and then transfected with 5 µg of the appropriate reporter and effector plasmids by the calcium phosphate method as described previously (9) .

ELISA.
LMP-1-transfected C33A cells were cultured with serum-free DMEM for 24 h. Then, the IL-8 content of the supernatants was measured using a specific ELISA assay kit (R&D Systems, Inc.) according to the manufacturer’s protocol.

Luciferase Reporter Assay.
Luciferase reporter assays were performed with extracts of C33A cells after transient transfection. Cells were incubated for 48 h after transfection, then harvested. Luciferase activity was quantified with a chemoluminometer (EG&G Berthold, Bad Wildbad, Germany).


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Immunohistochemical Features of LMP-1, Angiogenic Factors, and vWF.
LMP-1, VEGF, bFGF, IL-8, and vWF expression were examined by immunohistochemical staining on biopsy specimens of NPC. LMP-1, VEGF, bFGF, and IL-8 were localized on the cell surface and in the cytoplasm of the tumor cells. However, their distribution patterns were protein-specific. LMP-1 and IL-8 proteins were scattered throughout the tumor cells and showed no specific tendency in its distribution pattern. VEGF and bFGF proteins were diffusely detected and were mainly localized to the periphery of the tumor cells. Microvessels, indicated by vWF staining, were detected as scattered in the tumor cell nests and showed similar distribution to LMP-1 and IL-8 in the area. They were also detected at the tumor stroma encircling tumor cell nests and showed a distribution pattern similar to VEGF and bFGF in the area (Fig. 1)Citation . The data of expression scores are shown in Table 1Citation .



View larger version (166K):
[in this window]
[in a new window]
  		Fig. 1. Immunohistochemical detection of LMP-1 (A), IL-8 (B), VEGF (C), bFGF (D), and microvessels (E) in NPC. Original magnification, x200.

 

View this table:
[in this window]
[in a new window]
  		Table 1 Expression scores of LMP1, IL-8, VEGF, bFGF, and microvessel countsa

 
Relationship of LMP-1 to Microvessel Counts.
To examine the relevance of LMP-1 to the neovascularization of NPC, the expression score of LMP-1 and microvessel counts were evaluated. A significant relationship was observed between LMP-1 expression score and microvessel counts (P = 0.0003; Table 2Citation ). Regression analysis also showed a significant correlation between these two factors (Fig. 2a)Citation . These results suggested that the expression of LMP-1 protein is closely associated with angiogenesis in NPC.


View this table:
[in this window]
[in a new window]
  		Table 2 Relationship of LMP1, angiogenic factors, and microvessel counts to each other in NPCa

 


View larger version (19K):
[in this window]
[in a new window]
  		Fig. 2. Regression analysis of the relationship between expression of LMP-1 and microvessel count (a), LMP-1 and IL-8 (b), and IL-8 and microvessel count (c) in patients with NPC. The expression scores of LMP-1, IL-8, and microvessel counts were plotted and analyzed by Pearson’s correlation coefficient analyses.

 
Relationship of LMP-1 to Angiogenic Molecules.
To investigate the role of LMP-1 in the angiogenesis of NPC, the relationships of LMP-1 to IL-8, VEGF, and bFGF were then analyzed by immunostaining. The expression score of IL-8 was significantly correlated to that of LMP-1 (P < 0.0001; Table 2Citation ; Fig. 2bCitation ). The expression scores of both VEGF and bFGF were related to that of LMP-1, but their correlation was not statistically significant (P = 0.104 and P = 0.118, respectively). These results suggested the close association of LMP-1 and IL-8 protein expression in NPC.

Relationship of Angiogenic Molecules to Microvessel Counts.
The relevance of angiogenic factors to the angiogenesis of NPC was evaluated by studying the relationships of IL-8, VEGF, and bFGF expression scores to microvessel counts. The expression score of IL-8 was significantly correlated to microvessel counts (P = 0.0428; Table 2Citation ). Regression analysis also indicated a significant relationship between IL-8 and microvessel counts (Fig. 2c)Citation . Not only IL-8 but also the expression scores of both VEGF and bFGF showed significant correlation with microvessel counts (P = 0.0468 and P = 0.0309, respectively; Table 2Citation ). These results suggest that IL-8, VEGF, and bFGF contribute to microvessel development in NPC.

Induction of IL-8 by LMP-1.
Immunohistochemical analysis suggested a close relationship between LMP-1 and IL-8 protein expression. Therefore, we examined whether LMP-1 protein expression could induce IL-8 production by ELISA. There was no difference in the growth between the pcDNA3-transfected C33A cells and the pcLMP1-transfected C33A cells at the time of supernatant collection. Concentration of IL-8 in the supernatant of pcDNA3-transfected C33A was 1.2 pg/ml and that of IL-8 in the supernatant of pcLMP1-transfected C33A was 50 pg/ml. Thus, ~50-fold increase in IL-8 secretion was observed in the supernatant of LMP-1-transfected C33A cells (Fig. 3)Citation . This result indicated that LMP-1 induces IL-8 in C33A cells.



View larger version (10K):
[in this window]
[in a new window]
  		Fig. 3. Induction of IL-8 by LMP-1. pcDNA3 and pcLMP1 plasmids were transiently transfected in C33A cell, and IL-8 concentration in supernatants of culture mediums were measured by ELISA. pcDNA3 and pcLMP1, the concentration of IL-8 in the supernatant of either pcDNA3-transfected C33A cells or pcLMP1-transfected cells, respectively. The results of triplicate experiments are shown.

 
Transactivation of IL-8 Promoter by LMP-1.
To determine whether LMP-1 stimulates transcription from the IL-8 gene promoter, luciferase promoter assay was performed. Cotransfection of LMP-1 enhanced transcription from the IL-8 promoter by 7-fold. LMP-1 activates NF{kappa}B and c-jun kinase in C33A cells (10) . Mutation of the AP-1 site in the IL-8 promoter significantly reduced its activity in response to LMP-1 expression by 70%. However, mutation of the NF{kappa}B site in the IL-8 promoter completely abolished its activity in response to LMP-1 expression (Fig. 4)Citation . These results suggested that the binding site for NF{kappa}B in the IL-8 promoter is an essential element for the response to stimulation by LMP-1, and the binding site for AP-1 plays a partial role for the response to stimulation by LMP-1.



View larger version (14K):
[in this window]
[in a new window]
  		Fig. 4. Determination of responsive elements in the promoter of IL-8. Various types of chimeric luciferase plasmids were transiently cotransfected with pcDNA3 or pcDNA3-LMP1 into C33A cells. X axis, transfected reporter plasmids. pcDNA3, pcDNA3, used as a control vector, was cotransfected with IL-8 wild-type promoter. IL-8 WT, IL-8 wild-type promoter. IL-8 WT contains -130 to + 39 IL-8 promoter DNA sequence obtained from human genomic DNA. IL-8 AP-1 mut, IL-8 promoter with AP-1 mutation. IL-8 AP-1 mut contains mutated AP-1 binding sequence TGATATC in the IL-8 promoter sequence. IL-8 NF{kappa}B mut, IL-8 promoter with NF{kappa}B mutation. IL-8 NF{kappa}B mut contains mutated NF{kappa}B binding sequence TTAACTTTCC in the IL-8 promoter sequence. Luciferase activities were measured as described in "Materials and Methods." The results of triplicate experiments are shown.

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
The associations of neovascularization to both angiogenic and lymphatic metastases have been examined in many malignant tumors, and the contributions of angiogenic molecules such as VEGF, bFGF, and IL-8 to the metastatic potential of tumors have been reported (2 , 3) .

The present study suggested associations of VEGF, bFGF, and IL-8 to neovascularization in NPC. It is noteworthy that expression of LMP-1 was significantly correlated to both the expression of IL-8 and the microvessel count but not to the expression of VEGF nor bFGF. Although the number of NPC samples examined in this study was not sufficient to allow us to make definite conclusions, these results suggested that LMP-1 may contribute to angiogenesis in NPC through the induction of IL-8.

LMP-1 has an activated-tumor necrosis factor receptor-mimicking function, which induces activation of NF{kappa}B and AP-1 (16 , 17) . Recently, we reported induction of MMP9 by LMP-1, which was mediated by both NF{kappa}B and AP-1 and blocked by aspirin or I-{kappa}B (10 , 18 , 19) . Both binding sites for AP-1 and NF{kappa}B in the promoter of MMP-9 were indispensable for transactivation of the promoter by LMP-1. In contrast, the data presented here indicated that the NF{kappa}B binding site in the IL-8 promoter was essential for the response to LMP-1, and that the AP-1 binding site played only a partial role.

Many molecules, including cell-surface markers such as CD23, CD40, intercellular adhesion molecule-1, and the antiapoptotic protein bcl-2, are induced by LMP-1 in B lymphocytes (20, 21, 22) . However, LMP-1 does not always have a similar effect on cellular signal transduction in epithelial cells. Functional NF{kappa}B complexes are combinations of the various NF{kappa}B family proteins, and different NF{kappa}B family proteins have varied affects on different NF{kappa}B-responsive promoters. In epithelial cells, LMP-1 activates a different subset of NF{kappa}B family proteins from that in lymphocytes (23) . LMP-1 does not induce bcl-2 in epithelial cells but induces A-20 for preventing LMP-1-expressing cells from experiencing programmed cell death (24) . Thus, we should be aware of the cell type-specific function of LMP-1.

Eliopoulos et al. (25) reported that activation of p38 mitogen-activated protein kinase, as well as NF{kappa}B, by LMP-1, contributed to IL-8 production in epithelial cells. Recently, we also reported the up-regulation of cell motility by LMP-1 via ets-1 activation (9) . The multiple functions of LMP-1 could be largely attributable to the activation of NF{kappa}B and AP-1. However, all molecules modulated by LMP-1 have not yet been elucidated, and additional studies of the molecular mechanism of LMP-1-mediated transformation and tumor progression are required.

Despite much evidence which suggests the relationship of LMP1 to tumor initiation and progression, the relationship of LMP-1 to the clinical features of EBV-associated tumors have been a matter of issue. In this study, there was no statistically significant correlation between LMP-1 expression score and cervical lymph-node status (P = 0.07; data not shown). Presumably, LMP-1 could play some role in both tumorigenesis and metastasis. However, so many factors, such as hypoxia and personal immune system, would also influence the behavior of the tumor.

The results reported here add weight to the growing body of evidence suggesting a positive role of LMP-1 in invasion and metastasis. Metastatic potential of NPC might be reduced by the inhibition of the LMP-1-mediated signaling pathways.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom requests for reprints should be addressed, at Department of Otolaryngology, School of Medicine, Kanazawa University, 13-1 Takaramachi, Kanazawa 920-8641, Japan. Phone: 81-76-265-2413; Fax: 81-76-234-4265; E-mail: tomoy{at}med.kanazawa-u.ac.jp Back

2 The abbreviations used are: VEGF, vascular endothelial growth factor; bFGF, basic fibroblast growth factor; IL-8, interleukin 8; NPC, nasopharyngeal carcinoma; LMP-1, latent membrane protein-1; vWF, von Willebrand factor; NF-{kappa}B, nuclear factor {kappa}B; AP-1, activator protein; MMP, matrix metalloproteinase. Back

Received 1/29/01; revised 4/30/01; accepted 5/ 2/01.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Weidner N., Semple J. P., Welch W. R., Folkman J. Tumor angiogenesis and metastasis. N. Engl. J. Med., 324: 1-8, 1991.[Abstract]
  2. Belperio J. A., Keane M. P., Arenberg D. A., Addison C. L., Ehlert J. E., Burdick M. D., Strieter R. M. CXC chemokines in angiogenesis. J. Leukoc. Biol., 68: 1-8, 2000.[Abstract/Free Full Text]
  3. Carmeliet P., Jain R. K. Angiogenesis in cancer and other diseases. Nature (Lond.), 407: 249-257, 2000.[CrossRef][Medline]
  4. Kieff E. Epstein-Barr virus and its replication Field B. C. Knipe D. M. Howley P. M. eds. . Virology, Vol. 11: 2343-2396, Lippincott-Raven Press New York 1996.
  5. Osato T. Epstein-Barr virus infection and oncogenesis Osato T. Takada K. Tokunaga S. eds. . Epstein-Barr Virus and Human Cancer, : 3-16, Japan Scientific Societies Press Tokyo 1998.
  6. Fahraeus R., Rymo L., Rhim J. S., Klein G. Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus. Nature (Lond.), 345: 447-449, 1990.[CrossRef][Medline]
  7. Wang D., Liebowitz D., Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell, 43: 831-840, 1985.[CrossRef][Medline]
  8. Fahraeus R., Chen W., Trivedi P., Klein G., Obrink B. Decreased expression of E-cadherin and increased invasive capacity in EBV-LMP-transfected human epithelial and murine adenocarcinoma cells. Int. J. Cancer, 52: 834-838, 1992.[Medline]
  9. Kim K. R., Yoshizaki T., Miyamori H., Hasegawa K., Horikawa T., Furukawa M., Harada S., Seiki M., Sato H. Transformation of Madin-Darby canine kidney (MDCK) epithelial cells by Epstein-Barr virus latent membrane protein 1 (LMP1) induces expression of Ets1 and invasive growth. Oncogene, 19: 1764-1771, 2000.[CrossRef][Medline]
  10. Yoshizaki T., Sato H., Furukawa M., Pagano J. The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1. Proc. Natl. Acad. Sci. USA, 95: 3621-3626, 1998.[Abstract/Free Full Text]
  11. Liotta L. A., Steeg P. S., Stetler-Stevenson W. G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64: 327-336, 1991.[CrossRef][Medline]
  12. Horikawa T., Yoshizaki T., Sheen T. S., Lee S. Y., Furukawa M. Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma. Cancer (Phila.), 89: 715-723, 2000.[CrossRef][Medline]
  13. Yoshizaki T., Sato H., Maruyama Y., Murono S., Furukawa M., Park C. S., Seiki M. Increased expression of membrane type 1-matrix metalloproteinase in head and neck carcinoma. Cancer (Phila.), 79: 139-144, 1997.[CrossRef][Medline]
  14. Wakisaka N., Wen Q., Yoshizaki T., Nishimura T., Furukawa M., Kawahara E., Nakanishi I. Association of vascular endothelial growth factor expression with angiogenesis and lymph node metastasis in nasopharyngeal carcinoma. Laryngoscope, 109: 810-814, 1999.[CrossRef][Medline]
  15. Mukaida N., Shiroo M., Matsushima K. Genomic structure of the human monocyte-derived neutrophil chemotactic factor IL-8. J. Immunol., 143: 1366-1371, 1989.[Abstract]
  16. Eliopoulos A. G., Blake S. M., Floettmann E., Rowe M., Young L. S. Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2. J. Virol., 73: 1023-1035, 1999.[Abstract/Free Full Text]
  17. Mosialos G., Birkenbach M., Yalamanchili R., Van Arsdale T., Ware C., Kieff E. The Epstein-Bar virus transforming protein LMP-1 engages signaling proteins for the tumor necrosis factor receptor family. Cell, 80: 389-399, 1995.[CrossRef][Medline]
  18. Murono S., Yoshizaki T., Sato H., Takeshita H., Furukawa M., Pagano J. S. Aspirin inhibits tumor cell invasiveness induced by Epstein-Barr virus latent membrane protein 1 through suppression of matrix metalloproteinase-9 expression. Cancer Res., 60: 2555-2561, 2000.[Abstract/Free Full Text]
  19. Takeshita H., Yoshizaki T., Miller W. E., Sato H., Furukawa M., Pagano J. S., Raab-Traub N. Matrix metalloproteinase 9 expression is induced by Epstein-Barr 1 C-terminal activation region 1 and 2. J. Virol., 73: 5548-5555, 1999.[Abstract/Free Full Text]
  20. Dawson C. W., Rickinson A. B., Young L. S. Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature (Lond.), 344: 777-780, 2000.
  21. Henderson S., Rowe M., Gregory C., Croom-Carter D., Wanf F., Longnecker R., Kieff E., Rickinson A. B. Induction of bcl-2 expression by the Epstein-Barr virus latent membrane protein-1 protects infected B-cells from programmed cell death. Cell, 65: 1107-1115, 1991.[CrossRef][Medline]
  22. Wang F., Gregory C., Sample C., Rowe M., Liebowitz D., Murray R., Rickinson A., Kieff E. Epstein-Barr virus latent membrane protein (LMP1) and nuclear protein 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA2 and LMP1 cooperatively induce CD23. J. Virol., 64: 2309-2318, 1990.[Abstract/Free Full Text]
  23. Paine E., Scheinman R. I., Baldwin A. B., Raab-Traub N. Expression of LMP1 in epithelial cells leads to the activation of a selected subset of NF-{kappa}B/Rel family proteins. J. Virol., 69: 4512-4576, 1995.
  24. Laherty C. D., Hu H. M., Opipair A. W., Wang F., Dixt V. M. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor {kappa}B. J. Biol. Chem., 267: 24157-24160, 1992.[Abstract/Free Full Text]
  25. Eliopoulos A. G., Gallagher N. J., Blake S. M., Dawson C. W., Young L. S. Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J. Biol. Chem., 274: 16085-16096, 1999.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
A. Tsuji, N. Wakisaka, S. Kondo, S. Murono, M. Furukawa, and T. Yoshizaki
Induction of Receptor for Advanced Glycation End Products by EBV Latent Membrane Protein 1 and Its Correlation with Angiogenesis and Cervical Lymph Node Metastasis in Nasopharyngeal Carcinoma
Clin. Cancer Res., September 1, 2008; 14(17): 5368 - 5375.
[Abstract] [Full Text] [PDF]

Home page
 Lab AnimHome page
K.-P. N Chow, C C Wu, H Y Chang, C Chang, and Y S Chang
A simplified tumour model established via Epstein-Barr virus-encoded, nasopharyngeal carcinoma-derived oncogene latent membrane protein 1 in immunocompetent mice
Lab Anim, April 1, 2008; 42(2): 193 - 203.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. Hsu, S.-Y. Wu, S.-S. Chang, I.-J. Su, C.-H. Tsai, S.-J. Lai, A.-L. Shiau, K. Takada, and Y. Chang
Epstein-Barr Virus Lytic Transactivator Zta Enhances Chemotactic Activity through Induction of Interleukin-8 in Nasopharyngeal Carcinoma Cells
J. Virol., April 1, 2008; 82(7): 3679 - 3688.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Horikawa, J. Yang, S. Kondo, T. Yoshizaki, I. Joab, M. Furukawa, and J. S. Pagano
Twist and Epithelial-Mesenchymal Transition Are Induced by the EBV Oncoprotein Latent Membrane Protein 1 and Are Associated with Metastatic Nasopharyngeal Carcinoma
Cancer Res., March 1, 2007; 67(5): 1970 - 1978.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
G. K. Hong, P. Kumar, L. Wang, B. Damania, M. L. Gulley, H.-J. Delecluse, P. J. Polverini, and S. C. Kenney
Epstein-Barr Virus Lytic Infection Is Required for Efficient Production of the Angiogenesis Factor Vascular Endothelial Growth Factor in Lymphoblastoid Cell Lines
J. Virol., November 15, 2005; 79(22): 13984 - 13992.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
N. Wakisaka, S. Kondo, T. Yoshizaki, S. Murono, M. Furukawa, and J. S. Pagano
Epstein-Barr Virus Latent Membrane Protein 1 Induces Synthesis of Hypoxia-Inducible Factor 1{alpha}
Mol. Cell. Biol., June 15, 2004; 24(12): 5223 - 5234.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
J. Melchjorsen, L. N. Sorensen, and S. R. Paludan
Expression and function of chemokines during viral infections: from molecular mechanisms to in vivo function
J. Leukoc. Biol., September 1, 2003; 74(3): 331 - 343.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
P. Lu, Y. Nakamoto, Y. Nemoto-Sasaki, C. Fujii, H. Wang, M. Hashii, Y. Ohmoto, S. Kaneko, K. Kobayashi, and N. Mukaida
Potential Interaction between CCR1 and Its Ligand, CCL3, Induced by Endogenously Produced Interleukin-1 in Human Hepatomas
Am. J. Pathol., April 1, 2003; 162(4): 1249 - 1258.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Wakisaka, S. Murono, T. Yoshizaki, M. Furukawa, and J. S. Pagano
Epstein-Barr Virus Latent Membrane Protein 1 Induces and Causes Release of Fibroblast Growth Factor-2
Cancer Res., November 1, 2002; 62(21): 6337 - 6344.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yoshizaki, T.
Right arrow Articles by Furukawa, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yoshizaki, T.
Right arrow Articles by Furukawa, M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online